

Pharmacy Passages

Health Exchange Essential Health Benefit (EHB) Formulary Update

May 2026



The following formulary decisions and updates apply to **Optum Rx[®] standard EHB formularies.**

The Optum Rx Business Committee meets monthly to evaluate tier placements and new prescription products approved by the Food and Drug Administration (FDA). This committee makes decisions based on information and recommendations from the Optum Rx Pharmacy & Therapeutics Committee, comprised of independent physician providers and pharmacists.

The following are the strategic clinical decisions made in the past month. Your actual plan's copays and/or coinsurance may differ from those indicated depending on the selected plan design, which determines coverage and pharmacy provider(s).

The tier chart below does not necessarily correlate to Centers for Medicare and Medicaid Services (CMS) submission tiers.

HIX BASE (RxBuilder) tiers	HIX ENHANCED (RxBuilder) tiers
Generic = 1	Low-cost generic = LCG
Preferred brand = 2	Generic = 1
Non-preferred brand = 3	Preferred brand = 2
Specialty = 4	Non-preferred brand = 3
Both versions include preventive (PV) drugs which may have \$0 when health care reform requirements are met.	Specialty generic and specialty preferred brands = 4
Both versions may contain oral chemo (CM) tier if elected.	Specialty non-preferred brands = 5

Key

SP: Specialty pharmacy

PA: Prior authorization

ST: Step therapy

QL: Quantity limit

Down-tiers

Medications may move to a lower tier or be added to the formulary throughout the year, helping members take immediate advantage of cost savings.

Please note there are no new down-tiers at this time.

Up-tiers

Medications may move to a higher tier on Jan. 1.

Please note there are no up-tiers at this time.

New brand launches and new strengths

New brand name medications and new strengths launch throughout the year. Final coverage status for new medications is determined after thorough review by the Optum Rx Pharmacy & Therapeutics Committee. New brand launches may include Authorized Brand Alternatives.*

Therapeutic use	Medication name	EHB Base	EHB Enhanced	Programs				Effective date
				SP	PA	ST	QL	
Immunological Agents	Enoby (denosumab-qbde) prefilled syringe for SC injection	Tier 4	Tier 4	X	X	---	X	7/1/26
Musculoskeletal Agents	Xtrenbo (denosumab-qbde) SC injection	Tier 4	Tier 4	X	X	---	X	7/1/26

* Authorized Brand Alternatives (ABA), also referred to as Authorized Generics, are approved brand name medications marketed by either the brand company or another company. Although it does not have the brand name on its label, it is the exact same drug product as the brand product.

New generic launches

New generic medication launches occur throughout the year.

Therapeutic use	Generic medication name	Brand medication name	EHB Base	EHB Enhanced	Programs				Effective date
					SP	PA	ST	QL	
Antidiabetic Agents	dapagliflozin tablet	Farxiga	Tier 2	Tier 2	---	---	X	---	4/6/26

Therapeutic use	Generic medication name	Brand medication name	EHB Base	EHB Enhanced	Programs				Effective date
					SP	PA	ST	QL	
Neurological Agents	dapagliflozin-metformin ER tablet	Xigduo XR	Tier 2	Tier 2	---	---	X	---	4/8/26
Respiratory Agents	fluticasone propionate HFA inhaler	N/A	Tier 2	Tier 2	---	---	---	X	3/30/26
	ipratropium HFA inhaler	Atrovent HFA	Tier 3	Tier 3	---	---	---	X	3/13/26

PA Prior authorization

Prior authorization requires physicians to provide additional clinical information to verify member benefit coverage.

Please note there are no additions or removals of this restriction at this time.

ST Step therapy

Step therapy directs members to try a lower-cost alternative (Step 1) before a higher-cost medication (Step 2) may be eligible for coverage.

Please note there are no additions or removals of this restriction at this time.

QL Quantity limits

Quantity limits establish the maximum quantity of a drug that is covered within a specified timeframe.

Please note there are no additions or removals of this restriction at this time.

AR Age restrictions (this applies to a limited number of clinical programs)

Please note there are no additions or removals of this restriction at this time.

If you would like additional information that is not listed,
please contact your Optum Rx representative.

Optum Rx[®]

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2026 OptumRx, Inc. All rights reserved. WF21110258-EHB_260217 EHBMay2026